1.Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2008;28(2):413–37.
2.Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Bock A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114(4):936–42.
3.Jolles S, Orange JS, Gardulf A, Stein MR, Shapiro R, Borte M, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179(2):146–60.
4.Wasserman RL, Melamed I, Nelson RP, Jr., Knutsen AP, Fasano MB, Stein MR, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50(6):405–14.
5.Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol. 2010;30(2):301–7.
6.Bienvenu B, Cozon G, Mataix Y, Lachaud D, Alix A, Hoarau C, et al. Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients. J Clin Immunol. 2018;38(4):503–12.
7.Pac M, Bernatowska E. Rapid push: new opportunities in subcutaneous immunoglobulin replacement therapy. Central European Journal of Immunology. 2013;38 (3)(388–392.).
8.Sidhu J, Rojavin M, Pfister M, Edelman J. Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency. Biol Ther. 2014;4(1–2):41–55.
9.Shapiro RS. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics. Pediatr Allergy Immunol. 2013;24(1):49–53.
10.Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol. 2013;111(1):51–5.
11.Shapiro R. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Clin Exp Immunol. 2013;173(2):365–71.
12.Cozon GJN, Clerson P, Dokhan A, Fardini Y, Sala TP, Crave JC. In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations. Patient Prefer Adherence. 2018;12:423–9.
13.Jolles S, Sleasman JW. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach. Adv Ther. 2011;28(7):521–33.
14.Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, et al. The Use of Immunoglobulin Therapy for Patients With Primary Immune Deficiency: An Evidence-Based Practice Guideline. Transfus Med Rev. 2010;24(1):S28-S50.
15.Patel NC, Gallagher JL, Ochs HD, Prescott Atkinson T, Wahlstrom J, Dorsey M, et al. Subcutaneous Immunoglobulin Replacement Therapy with Hizentra(R) is Safe and Effective in Children Less Than 5 Years of Age. J Clin Immunol. 2015;35(6):558–65.
16.Espanol T, Prevot J, Drabwell J, Sondhi S, Olding L. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. Patient Prefer Adherence. 2014;8:621–9.
17.Petersson C, Fust R, Hagstedt C, Vagstrom P, Nilsdotter-Augustinsson A. “Experiences of the burden of treatment” - patient-reports of facilitated subcutaneous immunoglobulin treatment in adults with immunodeficiency. Journal of clinical nursing. 2018.
18.Jolles S. Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency. Immunotargets Ther. 2013;2:125–33.
19.Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23(1):55–60.
20.Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158 Suppl 1:51–9.
21.Paris K, Haddad E, Borte M, Brodszki N, Derfalvi B, Marodi L, et al. Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies. Immunotherapy. 2019;11(5):397–406.
22.Ponsford M, Carne E, Kingdon C, Joyce C, Price C, Williams C, et al. Facilitated subcutaneous immunoglobulin (fSCIg) therapy—practical considerations. Clin Exp Immunol. 2015;182(3):302–13.
23.Schmidt RE, Ochs HD. 7th International Immunoglobulin Conference: Immunodeficiencies. Clin Exp Immunol. 2014;178 Suppl 1:21.
24.Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951–7 e11.
25.Jolles S, Borte M, Nelson RP, Jr., Rojavin M, Bexon M, Lawo JP, et al. Long-term efficacy, safety, and tolerability of Hizentra(R) for treatment of primary immunodeficiency disease. Clin Immunol. 2014;150(2):161–9.
26.Kanegane H, Imai K, Yamada M, Takada H, Ariga T, Bexon M, et al. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases. J Clin Immunol. 2014;34(2):204–11.
27.van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35–46.
28.European Medicines Agency (EMA). Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg). 2015 [Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-human-normal-immunoglobulin-subcutaneous/intramuscular-administration-scig/imig_en.pdf.
29.Arias Pou P, Gonzalez A, Martinez LJP, Latorre AD, Alonso MS. Periprocedural management of patients receiving novel oral anticoagulants. European journal of hospital pharmacy Science and practice. 2018;25(6):292–7.
30.Food and Drug Administration (FDA). Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency 2008 [Available from: https://www.fda.gov/media/124333/download.
31.Pasquet M, Pellier I, Aladjidi N, Auvrignon A, Cherin P, Clerson P, et al. A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions? Patient Prefer Adherence. 2017;11:1171–80.